BX LAB TECHNICAL ARTICLE
INTerpath-001 Is Positive, but the Phase 3 Effect Size Is Still Missing
INTerpath-001 met RFS and DMFS endpoints, but Phase 3 effect sizes, subgroup results and mature overall survival data remain pending.
Key takeaways
The prespecified interim analysis met RFS and DMFS endpoints, according to Merck and Moderna.
No Phase 3 hazard ratios, confidence intervals, survival curves or detailed safety results have been released.
Phase 2b effect sizes and registry-level program counts should not be treated as estimates of the Phase 3 benefit.
What INTerpath-001 tested
INTerpath-001 evaluates intismeran autogene with pembrolizumab after complete resection of high-risk Stage IIB-IV cutaneous melanoma. The randomized, double-blind Phase 3 study assigned participants 2:1 to intismeran plus pembrolizumab or placebo plus pembrolizumab. The company reports 1,137 enrolled; the older registry snapshot lists an estimated 1,089 across 165 locations.
What the announcement does not yet show
The topline announcement provides no Phase 3 hazard ratios, confidence intervals, Kaplan-Meier curves, subgroup results or detailed safety table. Overall survival remains under evaluation. The result supports a specific conclusion—that RFS and DMFS endpoints were met at an interim analysis—not an OS benefit, approval or new standard of care.
Phase 2b provides context, not a Phase 3 estimate
At five-year follow-up in KEYNOTE-942, the companies reported RFS HR 0.51, DMFS HR 0.411 and exploratory OS HR 0.471 with a confidence interval crossing 1. The Phase 2b study was smaller, open-label and enrolled a different stage mix, so its estimates cannot substitute for the missing confirmatory results.
The wider program is substantial, but outcomes remain study-specific
A retained ClinicalTrials.gov API query returned 12 V940 or mRNA-4157 studies totaling 5,137 planned or actual participants. Five records include a Phase 3 designation; one is the terminated Phase 2/3 INTerpath-007 record with 46 actual participants, while the other four total 3,513. These counts describe program scale rather than clinical success, and no reason should be inferred for termination when the registry provides none.
The research-materials boundary needs to remain explicit
The company says intismeran encodes up to 34 neoantigens, but the public announcement does not disclose detailed nucleotide chemistry, capping, lipid composition or full manufacturing specifications. Generic mRNA workflow materials must not be presented as the composition of intismeran, and no BX Lab catalog material is claimed as part of the investigational product.
What to watch next
The full presentation should provide effect sizes, absolute event rates, confidence intervals, curve separation, subgroup consistency, detailed safety and OS maturity. Regulatory submissions and decisions should be assessed from their own records rather than anticipated from the topline release.
References
Technical context is supported by the peer-reviewed literature below.